Sobrera Pharma develops an effective new pharmacotherapy for patients with moderate to severe alcohol use disorders. With this therapy, patients will achieve a long-lasting reduction in alcohol consumption. The product can significantly improve efficacy compared to currently existing treatments. The product is a combination of two existing drugs that provide complementary effect on the alcohol demand.
Impact: Patients will achieve a long-lasting reduction in alcohol consumption and achieve abstinence.
Stage: Phase ll study ongoing
CEO: Ann-Charlotte Rosendahl
GUV Conctact: Anders Waas
Location: Sweden, Gothenburg
Employees: 1-10